Edmonton's General Intermediates of Canada Inc. (GIC) has received conditional funding from the National Research Counci...
Roche recently announced that the China National Drug Administration (CNDA) has granted marketing authorization fo...
HitGen Ltd has announced a multi-year major drug discovery research collaboration with LG Chem to identify novel small m...
Blueberry Therapeutics Limited, a drug discovery and development company focused on developing innovative nanomedicines ...
The Buck Institute, Juvenescence, and Insilico Medicine have announced a research collaboration utilizing artificial int...
Singapore – The U.S. Food and Drug Administration recently approved Galafold (migalastat), the first oral medicati...
Pfizer China announced that the China National Drug Administration (CNDA) has granted approval of IBRANCE® (palbocic...
Singapore – DotBio, a new company focused on the development of novel immuno-oncology drugs based on humanize...
MedPacto, that announced today a clinical collaboration with AstraZeneca to evaluate the safety and efficacy of MedPacto...
Singapore – The European Commission approves Pfizer's TRAZIMERA, a biosimilar of Roche's cance...
Singapore- The FDA accepts for review Nektar Therapeutics' marketing application seeking approval for NK...
Singapore – The FDA approves Agios Pharmaceuticals' TIBSOVO (ivosidenib) for the treatment of adult pati...
Singapore – US Food and Drug Administration approves Pfizer’s Neupogen biosimilar Nivestym and is expected t...
Singapore – The U.S. Food and Drug Administration approved TPOXX (tecovirimat), the first drug wit...
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-c...
Singapore – Eagle Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted seve...
OBI Pharma, a Taiwan biopharma company, has announced that the U.S. Food and Drug Administration (FDA) has gra...
Singapore – Eisai and Biogen have announced positive topline results from the Phase II study with BAN2401, an...
